Sep 01, 2015 7:00 am EDT Heat Biologics Announces Clinical Trial Combining HS-110 and PD-1 Checkpoint Inhibitor in NSCLC
Aug 13, 2015 8:00 am EDT Heat Biologics Announces Financial Results for the Second Quarter Ended June 30, 2015
Jul 27, 2015 8:00 am EDT Heat Biologics, Inc. Announces Promotions of Taylor Schreiber, M.D., Ph.D., to Chief Scientific Officer, and Melissa Price, Ph.D., to Vice President of Product Development
Jul 01, 2015 8:00 am EDT Heat Biologics, Inc. to Present at the Cantor Fitzgerald Healthcare Conference
Jun 15, 2015 7:00 am EDT Heat Biologics Announces Development of ComPACT, a Next Generation Combination Immunotherapy Platform
May 29, 2015 8:00 am EDT Heat Biologics, Inc. to Present Interim Immune Response Data From Ongoing Phase II Trial With HS-110 in Advanced NSCLC at ASCO
May 14, 2015 8:00 am EDT Heat Biologics Announces Financial Results for the First Quarter Ended March 31, 2015
May 11, 2015 2:04 pm EDT CORRECTING and REPLACING -- Heat Biologics Announces Initiation of Phase 1b Trial of Viagenpumatucel-L (HS-110) in Non-Small Cell Lung Cancer (NSCLC)
May 11, 2015 2:04 pm EDT Heat Biologics Announces Initiation of Phase 1b Trial of Viagenpumatucel-L (HS-110) in Non-Small Cell Lung Cancer (NSCLC)